GSK vaccine brief pending

Pharmaceutical giant GlaxoSmithKline has put the global account for cervical cancer vaccine Cervarix out to pitch.

The six-figure PR account is currently held by Cohn & Wolfe. It is understood to include issues work and public affairs activity in most global markets outside the US.

GSK's vaccine hit the headlines in June when the Department of Health chose it over rival Sanofi Pasteur's product for use in a schoolgirl vaccination programme.

GSK is in discussions with agencies. It will then create a shortlist and brief agencies for a pitch before Christmas.

Clew Communications handles the core UK PR brief for Cervarix and is not affected.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in